ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025

Join Novalix at the ACSMEDI-EFMC Medicinal Chemistry Frontiers in Chicago, IL. This event is co-organized by ACSMEDI (Division of Medicinal Chemistry of the American Chemical Society), and EFMC (European Federation for Medicinal Chemistry and Chemical Biology).

“Combining DEL, AI, and medicinal chemistry: the winning synergy in drug discovery”

We are excited to announce that Dr Dhoha Triki, Senior Scientist in Computational Chemistry, will deliver an oral communication entitled: “Combining DEL, AI, and medicinal chemistry: the winning synergy in drug discovery”:

• on May 13, 2025
  at 12:00 p.m.
  in Session 2 – Artificial Intelligence in Drug Discovery
  Ref. OC03

“Identification of a submicromolar BRD4 PROTAC degrader from a moderately potent DEL Hit: harnessing the synergy of DEL and PROTAC technologies”

Don’t miss our scientific poster presentation highlighting how a DEL screen of 30 million compounds led to micromolar hits—rapidly optimized into a submicromolar BRD4 PROTAC degrader using the Novalix PROTAC toolbox. This work showcases the potential of moderately potent binders in enabling efficient targeted protein degradation.

Introduction: DEL technology has established itself as a method of choice for binder identification across a broad variety of protein targets. Novalix adopted several years ago a differentiating strategy focused on producing druglike and diverse hits with ADME-proof properties. This diversity and drug-likeness are ensured through stringent selection of building blocks (BBs) and careful design of DEL libraries.
Novalix has built and continuously expanded a DEL platform, which now comprises over 250 million compounds from 12 DEL libraries.

In addition to the conventional optimization of hits into small molecule preclinical candidates, the DEL approach offers direct access to transforming hits into PROTAC degraders, thanks to the pre-existing exit vector constituted by the headpiece and the DNA tag. Novalix has developed a PROTAC platform that integrates various expertise and capabilities to address a PROTAC approach.
Consequently, a PROTAC toolbox comprising more than 400 PROTAC precursors covering four of the most common E3 ligases has been produced. This allows for the direct assembly of final PROTAC degraders from the initial hit in just a couple of steps, without the need for SAR
investigations on the initial hit.
As a proof of concept to validate the efficacy of both platforms and demonstrate their perfect complementarity, a BRD4 case study was developed.”

More details on Medicinal Chemistry Frontiers

Renowned speakers will present their latest results and the emerging trends in medicinal chemistry and drug discovery. ACSMEDI-EFMC Medicinal Chemistry Frontiers Meeting attracts experts, researchers and early career trainees in drug discovery and development, such as medicinal and synthetic chemists, and scientists in computer assisted drug design, biology, DMPK, pharmacology, and early toxicology.

– high quality plenary lectures
– sessions on key topics
– oral communications
– an extensive social program to maximize networking opportunities
– a poster session
– a commercial exhibition

Meet us at our booth #8

Come and visit us at booth No. 8 during Medicinal Chemistry Frontiers.
Just contact us to set up a meeting and catch up!